Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib Monotherapy in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
NCT05274997Phase 2Unknown
- Sponsor
- Yingli Pharma
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of linperlisib in peripheral T-cell lymphoma (PTCL), natural killer cell lymphoma and cutaneous T-cell lymphoma (CTCL), sponsored by Yingli Pharma. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
linperlisib
03
Conditions
peripheral T-cell lymphoma (PTCL)natural killer cell lymphomacutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05274997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274997.